Cancer treatment access roundtable more important than ever following death of Australian advocate

Rare Cancers Australia’s upcoming policy roundtable is particularly timely following the death of leading rare cancer advocate, Caitlin Delaney AM.

Diagnosed with a rare ovarian cancer when she was 39, Caitlin lived almost a decade with advanced cancer. She died last week.

Caitlin championed the need for faster, fairer, more equitable access to treatment, having spent hundreds of thousands of dollars on treatments that gave her more time with her young daughters and husband. She was a leading advocate and changemaker, and continued her advocacy until her final hours, urging that “the word ‘rare’ must stop being an excuse to look away”.

RCA will bring together lived experience advocates, government, clinicians, researchers and industry in Sydney and online on Wednesday 18 November to discuss and design an Australian Rare Cancer Therapies Access Accelerator (RaCTAA).

The RaCTAA is a key recommendation from RCA’s recent policy report, From rare to recognized: The changing story of cancer, and would provide patients with earlier subsidized access to treatments, while generating the data and evidence needed to improve reimbursement, research and clinical care.

Rare and less common cancers accounted for one in four cancer diagnoses in Australia last year, but a disproportionate one in three cancer deaths. Relative five-year survival for these cancers is improving far more slowly than for our most common cancers.

RCA CEO, Christine Cockburn, said people with rare and less common cancers often faced enormous challenges in accessing treatments in an outdated system built for more common conditions.

Caitlin was a rare champion in every way, but she shouldn’t have needed to push so hard. Since the day Rare Cancers Australia was founded, 15 years ago, we’ve advocated for faster and fairer access to cancer therapies. Too many people have died waiting.”

Christine Cockburn, CEO, Rare Cancers Australia

Alongside reforms to Australia’s Health Technology Assessment system, Ms. Cockburn said a RaCTAA would help people with rare cancers access treatments that could extend and improve their lives, without prohibitive personal costs.

“Australia needs a proactive strategy that embraces innovation, accelerates evidence generation, and ensures promising therapies reach people with rare cancers sooner. We can lead the way on rare cancers,” Ms. Cockburn said.

“The RaCTAA is a mechanism for different funding pathways, data collection and use, and evidence generation that will finally lift rare cancers out of the too-hard pile and into the light.”

“Caitlin should have been at the roundtable. She and so many in the rare cancer community are deeply passionate about the promise of this reform. We will continue to advocate until every person with cancer has the best chance of survival, no matter how rare their diagnosis is.”

Throughout the day, attendees will hear from expert speakers and take part in breakout discussions to establish principles for a RaCTAA.

Speakers include:

  • Sarah McGoram OAM, Rare Advocate and President of the Patient Voice Initiative
  • Lauren Rayner, Rare Advocate
  • Associate Professor James Lynam, Senior Clinical Advisor for the Cancer Institute NSW and Chair, Medical Oncology Group of Australia
  • Professor Clare Scott, Chair of the Australia and New Zealand Gynaecological Oncology Group and Laboratory Head, Walter and Eliza Hall Institute of Medical Research
  • Andrew Rintoul, Assistant Secretary, Office of Health Technology Assessment – Australian Government Depart of the Health, Disability and Ageing
  • Steve Williamson, Associate Director, Managed Access and Medicine Policy, National Institute for Health and Care Excellence
  • Professor Andrew Wilson, Co-Director of the Leeder Centre for Health Policy, Economics and Data at the University of Sydney and Professor of Public Health in the Sydney School of Public Health
  • Sarah Norris, Associate Professor of Health Technology Assessment, Economics and Data, University of Sydney; Co-Deputy Chair, Medical Services Advisory Committee (MSAC); Chair, MSAC Evaluation Subcommittee
  • Brendan Shaw, Shawview Consulting
  • Tobias J Schulz, Health Policy and Governance Specialist
  • Dr Vickyanne Curruthers, Paediatric Medical Oncologist and National Principal Investigator of SACHA: A Paediatric Cancer Registry
  • Dr Ben Daniels, Senior Research Fellow, UNSW, School of Population Health

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
New prostate cancer guidelines provide concrete roadmap for patient screening